eRF3 is an interacting partner of survivin, and both—together with anti-survivin antibodies—are prognostic biomarkers in RA, suggesting that the autoantibody response in RA might be directed against a protein complex of GSPT2 and survivin. Here, BIRC5 is linked to rheumatoid arthritis.